A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer - Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ; Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ; Planchard, David (Institut Gustave Roussy (Villejuif, França)) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ; Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ; Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ; Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ; Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ; Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ; Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ; Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ; Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ; Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ; Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona